Session VII: Colorectal Cancer II

SESSION VII WEBCAST

FULL ABSTRACTS AVAILABLE SATURDAY JULY 4

Late-Breaking Abstract-6: Safety, feasibility, tolerability, and preliminary efficacy of perioperative systemic therapy for resectable colorectal peritoneal metastases: pilot phase of a randomised trial (CAIRO6)

 

Short Oral-24: AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: results from the CodeBreak 100 phase 1 trial

 

AMG 510/Sotorasib

 

Servier Satellite Symposium:

Short Oral-25: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701)

 

Short Oral-26: Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer Patients

 

Short Oral-28: A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer (mCRC)

 

Short Oral-29: Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study

 

Short Oral-30: Adjuvant systemic chemotherapy versus active surveillance following upfront resection of isolated synchronous colorectal peritoneal metastases: propensity score-matched analysis of a nationwide registry.

 

Short Oral-31: Centralization of care leads to optimal selection and outcomes for patients with peritoneal metastases of colorectal cancer- the Catalonian regional program experience

 

Short Oral-32: Biomarker analysis of the Phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC

 

Short Oral-33: Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line Therapy

 

Short Oral-34: Clinical experience of a personalized and tumor-informed circulating tumor DNA assay for minimal residual disease detection in oligometastatic colorectal cancer patients

 

Short Oral-35: Tumor infiltrating CD3 lymphocytes and CD68 macrophages are associated with long-time survival in metastatic colorectal cancer patients treated with chemotherapy

 

Short Oral-36: The prognostic impact of mismatch repair phenotype in colon cancer is highly stage dependent.

 

Oral-20: Phase I/IB study of regorafenib and nivolumab in mismatch repair (MMR) proficient advanced refractory colorectal cancer

 

Oral-21: METABEAM Study: combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites